Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ ELOF1 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA568347
Description
Predicted to react with Mouse and Rat samples.
Eukaryotic RNA polymerase II mediates the synthesis of mature and functional messenger RNA. This is a multistep process, called the transcription cycle, that includes five stages: preinitiation, promoter, clearance, elongation and termination. Elongation is thought to be a critical stage for the regulation of gene expression. ELOF1 (Transcription elongation factor 1 homolog) is a 83 amino acid nuclear protein that is implicated in the maintenance of proper chromatin structure in regions that are being actively transcribed. The gene encoding ELOF1 maps to human chromosome 19, which consists of over 63 million bases, houses approximately 1,400 genes and is recognized for having the greatest gene density of the human chromosomes. It is the genetic home for a number of immunoglobulin (Ig) superfamily members, including the killer cell and leukocyte Ig-like receptors, a number of ICAMs, the CEACAM and PSG family and Fc receptors (FcRs).
Specifications
ELOF1 | |
Polyclonal | |
Unconjugated | |
ELOF1 | |
1110011K10Rik; ELF1; ELF1 homolog, elongation factor 1; ELOF1; elongation factor 1 homolog; elongation factor 1 homolog (ELF1, S. cerevisiae); elongation factor 1 homolog (S. cerevisiae); RGD1309855; transcription elongation factor 1 homolog | |
Rabbit | |
Affinity chromatography | |
RUO | |
66126, 691193, 84337 | |
-20°C | |
Liquid |
Western Blot | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
P60002, P60003 | |
ELOF1 | |
Synthesized peptide derived from human ELOF1. | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction